Figure S5 from FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer

Yu-Zhou Huang,Ming-Yi Sang,Pei-Wen Xi,Ruo-Xi Xu,Meng-Yuan Cai,Zi-Wen Wang,Jian-Yi Zhao,Yi-Han Li,Ji-Fu Wei,Qiang Ding

DOI: https://doi.org/10.1158/0008-5472.27231244

2024-01-01

Abstract:Figure S5 presents a comprehensive analysis of the interaction between FANCI and PARP1.

What problem does this paper attempt to address?

Figure S2 from FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer

Yu-Zhou Huang,Ming-Yi Sang,Pei-Wen Xi,Ruo-Xi Xu,Meng-Yuan Cai,Zi-Wen Wang,Jian-Yi Zhao,Yi-Han Li,Ji-Fu Wei,Qiang Ding

DOI: https://doi.org/10.1158/0008-5472.27231253

2024-01-01

Abstract:Figure S2 depicts the expression patterns of FANCI among breast cancer patient groups based on clinical parameters.
Figure S7 from FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer

Yu-Zhou Huang,Ming-Yi Sang,Pei-Wen Xi,Ruo-Xi Xu,Meng-Yuan Cai,Zi-Wen Wang,Jian-Yi Zhao,Yi-Han Li,Ji-Fu Wei,Qiang Ding

DOI: https://doi.org/10.1158/0008-5472.27231238

2024-01-01

Abstract:Figure S7 illustrates the enhanced sensitivity of breast cancer cells to talazoparib by FANCI knockdown.
Abstract 7220: Emerging combination strategy: FANCI suppression induces PARP1 redistribution to enhance efficacy of PARP inhibitors in breast cancer

Yu-zhou Huang,Ming-Yi Sang,Pei-Wen Xi,Ruo-Xi Xu,Meng-Yuan Cai,Zi-Wen Wang,Jian-Yi Zhao,Yi-Han Li,Ji-Fu Wei,Qiang Ding

DOI: https://doi.org/10.1158/1538-7445.am2024-7220

IF: 11.2

2024-03-24

Cancer Research

Abstract:While polyADP-ribose polymerase (PARP) inhibitors have made advancements in the treatment of breast cancer, challenges such as chemotherapy resistance and limited application persist. Fanconi AnemiaComplementation Group I (FANCI), a DNA repair protein associated with breast cancer development, represents a potential target for novel combination therapeutic strategies. However, the role of FANCI in breast cancer and its impact on the efficacy of PARP inhibitors require further investigation. In our study, we analyzed FANCI expression in breast cancer tissues and cell lines, and its correlation with clinical parameters and patient prognosis. Lentiviral vectors were utilized and functional assays were performed to evaluate the effects of FANCI modulation on breast cancer cell growth and migration. Co-immunoprecipitation assays and protein interaction analysis were conducted to identify the interaction between FANCI and PARP1 and determine the specific binding region. The functionality and nuclear distribution of PARP1 were assessed upon FANCI modulation. Finally, the sensitivity of breast cancer cells to the PARP inhibitor talazoparib upon FANCI knockdown was evaluated in vitro and in vivo. Our findings demonstrated that FANCI was overexpressed in breast cancer and associated with poor prognosis. FANCI significantly promoted breast cancer cell proliferation both in vitro and in vivo. We identified the interaction between FANCI and PARP1, specifically at the FANCI helical domain 2 binding site. FANCI knockdown led to reduced nuclear localization of PARP1 and decreased PARP1 activity. Importantly, combination treatment with FANCI knockdown and talazoparib significantly inhibited cancer growth in vitro and in vivo. Additionally, we found that the cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib, which effectively suppresses FANCI protein expression, exhibited a robust synergistic effect with talazoparib both in vitro and in vivo. In conclusion, FANCI is a novel therapeutic target for breast cancer. Suppression of FANCI regulates PARP1 redistribution and activity, making breast cancer cells more responsive to PARP inhibitors. This combination therapeutic strategy shows potential in enhancing the effectiveness of PARP inhibitors for breast cancer treatment, regardless of BRCA mutations. Citation Format: Yu-zhou Huang, Ming-Yi Sang, Pei-Wen Xi, Ruo-Xi Xu, Meng-Yuan Cai, Zi-Wen Wang, Jian-Yi Zhao, Yi-Han Li, Ji-Fu Wei, Qiang Ding. Emerging combination strategy: FANCI suppression induces PARP1 redistribution to enhance efficacy of PARP inhibitors in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7220.

oncology
Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528434.v1

2023-01-01

Abstract:<p>PDF file, 81K, Effect of PARP inhibition in combination with standard chemotherapy.</p>
FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells

Ke Cong,Nathan MacGilvary,Silviana Lee,Shannon G. MacLeod,Jennifer Calvo,Min Peng,Arne Nedergaard Kousholt,Tovah A. Day,Sharon B. Cantor

DOI: https://doi.org/10.1038/s41467-024-46824-5

IF: 16.6

2024-03-23

Nature Communications

Abstract:Abstract The effectiveness of poly (ADP-ribose) polymerase inhibitors (PARPi) in creating single-stranded DNA gaps and inducing sensitivity requires the FANCJ DNA helicase. Yet, how FANCJ relates to PARP1 inhibition or trapping, which contribute to PARPi toxicity, remains unclear. Here, we find PARPi effectiveness hinges on S-phase PARP1 activity, which is reduced in FANCJ deficient cells as G-quadruplexes sequester PARP1 and MSH2. Additionally, loss of the FANCJ-MLH1 interaction diminishes PARP1 activity; however, depleting MSH2 reinstates PARPi sensitivity and gaps. Indicating sequestered and trapped PARP1 are distinct, FANCJ loss increases PARPi resistance in cells susceptible to PARP1 trapping. However, with BRCA1 deficiency, the loss of FANCJ mirrors PARP1 loss or inhibition, with the detrimental commonality being loss of S-phase PARP1 activity. These insights underline the crucial role of PARP1 activity during DNA replication in BRCA1 deficient cells and emphasize the importance of understanding drug mechanisms for enhancing therapeutic response.

multidisciplinary sciences
Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

Tao Zhu,Ju-Yan Zheng,Ling-Ling Huang,Yan-Hong Wang,Di-Fei Yao,Hai-Bin Dai

DOI: https://doi.org/10.3389/fphar.2023.1137151

IF: 5.6

2023-01-01

Frontiers in Pharmacology

Abstract:Poly (ADP-ribose) polymerase 1 (PARP1) is a key DNA damage sensor that is recruited to damaged sites after DNA strand breaks to initiate DNA repair. This is achieved by catalyzing attachment of ADP-ribose moieties, which are donated from NAD+, on the amino acid residues of itself or other acceptor proteins. PARP inhibitors (PARPi) that inhibit PARP catalytic activity and induce PARP trapping are commonly used for treating BRCA1/2-deficient breast and ovarian cancers through synergistic lethality. Unfortunately, resistance to PARPi frequently occurs. In this review, we present the novel substrates and regulators of the PARP1-catalyzed poly (ADP-ribosyl)ation (PARylatison) that have been identified in the last 3 years. The overall aim is the presentation of protein interactions of potential therapeutic intervention for overcoming the resistance to PARPi.
Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren Averett Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528440.v1

2023-01-01

Abstract:PDF file, 125K, Western blot of total PARP1.
PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Xiaolei Zhu,Xiaodong Ma,Yongzhou Hu

DOI: https://doi.org/10.2174/0929867321666140915143516

IF: 4.74

2016-01-01

Current Medicinal Chemistry

Abstract:Poly(ADP-ribose) polymerase 1 (PARP1) inhibition, increasing chemosensitization and conferring independent antiproliferation against defective homologous recombination cells, has provided a unique opportunity for anticancer therapeutic intervention. Therefore, PARP1, the best characterized enzyme among PARP family, is presently serving as a well-established target for the treatment of oncology attributed to its intimate role in DNA repair. Nowadays, intensified medicinal chemistry efforts have led to the discovery of 12 PARP1 inhibitors that have been advanced into clinical trial. In this article, we classify these candidates as three categories based on the chemical structure, including lactam type, pseudo ring type and untypical PARP1 inhibitors, for a sequential overview of them. In particular, the development of some candidates will serve the purpose for the future exploration of PARP1 inhibitors.
FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways

Shi-Qi Wu,Shi-Hui Huang,Qian-Wen Lin,Yi-Xuan Tang,Lei Huang,Yun-Gen Xu,Shu-Ping Wang

DOI: https://doi.org/10.1016/j.phrs.2021.106040

IF: 10.334

2022-01-01

Pharmacological Research

Abstract:Inducing homologous recombination (HR) deficiency is a promising strategy to broaden the indication of PARP1/2 inhibitors in pancreatic cancer treatment. In addition to inhibition kinases, repression of the transcriptional function of FOXM1 has been reported to inhibit HR-mediated DNA repair. We found that FOXM1 inhibitor FDI-6 and PARP1/2 inhibitor Olaparib synergistically inhibited the malignant growth of pancreatic cancer cells in vitro and in vivo. The results of bioinformatic analysis and mechanistic study showed that FOXM1 directly interacted with PARP1. Olaparib induced the feedback overexpression of PARP1/2, FOXM1, CDC25A, CCND1, CDK1, CCNA2, CCNB1, CDC25B, BRCA1/2 and Rad51 to promote the acceleration of cell mitosis and recovery of DNA repair, which caused the generation of adaptive resistance. FDI-6 reversed Olaparib-induced adaptive resistance and inhibited cell cycle progression and DNA damage repair by repressing the expression of FOXM1, PARP1/2, BUB1, CDC25A, BRCA1 and other genes-involved in cell cycle control and DNA damage repair. We believe that targeting FOXM1 and PARP1/2 is a promising combination therapy for pancreatic cancer without HR deficiency.

pharmacology & pharmacy
Targeting FEN1 to enhance efficacy of PARP inhibition in triple-negative breast cancer

Mallory I Frederick,Elicia Fyle,Anna Clouvel,Djihane Abdesselam,Saima Hassan

DOI: https://doi.org/10.1101/2024.10.01.616136

2024-10-03

Abstract:Patients with triple-negative breast cancer (TNBC) have limited targeted therapeutic options. PARP inhibitors (PARPi) have demonstrated an important role for BRCA-mutant patients with early TNBC. Combination approaches with PARPi can broaden the use of PARPi to a larger cohort of TNBC patients. We selected six genes from our previously identified 63-gene signature that was associated with PARPi response. siFEN1 increased cells in G2/M arrest, DNA damage and particularly apoptosis. Targeting FEN1 with a chemical inhibitor enhanced the efficacy of PARPi in 7/10 cell lines, and synergy was demonstrated mainly in PARPi-resistant TNBC cell lines. A BRCA2-mutant cell line with acquired resistance to olaparib (HCC1395-OlaR) was strongly synergistic, with a combination index value of 0.20. The combination of PARPi and FEN1 inhibition also showed synergy in a PARPi-resistant xenograft-derived organoid model. Two mechanisms which explain the underlying efficacy are rapid progression in DNA replication fork speed and enhancement of DNA damage. The combination induced the highest fork speed (47% difference in comparison to control, P<0.0001) when FEN1 inhibition and PARPi equally increased fork speed individually in a cell line with a pre-existing increase in replication stress. The combination also increased DNA damage at lower drug concentrations, driving response in most of the synergistic cell lines. Gene expression analysis suggested that the sensitizing role of FEN1 inhibition in PARPi-resistant cell lines may be due to downregulation of pathways including mismatch repair. Therefore, targeting FEN1 shows great therapeutic potential as a targeted combination approach, particularly in the context of PARPi-resistant TNBC.

Cancer Biology
BRMS1 Participates in Regulating Cell Sensitivity to DNA Interstrand Crosslink Damage by Interacting with FANCI

Jianming Dou,Yiren Zhou,Xuni Liu,Xiaojing Qiao,Xi Yang,Wenjuan Xie,Shouyi Qiao,Yanhua Wu

DOI: https://doi.org/10.3892/or.2018.6816

2018-01-01

Oncology Reports

Abstract:Breast cancer metastasis suppressor 1 (BRMS1) is a tumor metastasis suppressor implicated in multiple steps during the metastatic cascade. Many proteins interacting with BRMS1 have been identified to unravel the intracellular signaling mechanisms. In the present study, we report that FANCI is a novel interacting protein of BRMS1 as determined by co-immunoprecipitation assay. The linker region between two coiled-coil motifs of BRMS1 is required for BRMS1-FANCI interaction. FANCI is an essential protein in the Fanconi anemia (FA) pathway responsible for the repair of DNA interstrand crosslinks (ICLs). We demonstrated that knockdown or knockout of BRMS1 significantly diminished the monoubiquitination of FANCI and FANCD2 in response to DNA ICL damage. BRMS1-deficient cells exhibited suppressed FANCD2 foci formation and hypersensitivity to ICLs. Moreover, rescue assays by utilizing different BRMS1 constructs suggested that BRMS1-FANCI interaction is necessary for the regulatory role of BRMS1 in the FA pathway. Overall, our findings characterize BRMS1 as a novel regulatory protein functioning in the DNA repair pathway via protein interaction.
A two-step mechanism governing PARP1-DNA retention by PARP inhibitors

Huijun Xue,Amit Bhardwaj,Yandong Yin,Carel Fijen,Anastasiya Ephstein,Lianglin Zhang,Xia Ding,John M Pascal,Todd L VanArsdale,Eli Rothenberg,John M. Pascal,Todd L. VanArsdale

DOI: https://doi.org/10.1126/sciadv.abq0414

IF: 13.6

2022-09-08

Science Advances

Abstract:PARP inhibitors (PARPi) have emerged as promising cancer therapeutics capable of targeting specific DNA repair pathways, but their mechanism of action with respect to PARP1-DNA retention remains unclear. Here, we developed single-molecule assays to directly monitor the retention of PARP1 on DNA lesions in real time. Our study reveals a two-step mechanism by which PARPi modulate the retention of PARP1 on DNA lesions, consisting of a primary step of catalytic inhibition via binding competition with NAD + followed by an allosteric modulation of bound PARPi. While clinically relevant PARPi exhibit distinct allosteric modulation activities that can either increase retention of PARP1 on DNA or induce its release, their retention potencies are predominantly determined by their ability to outcompete NAD + binding. These findings provide a mechanistic basis for improved PARPi selection according to their characteristic activities and enable further development of more potent inhibitors.

multidisciplinary sciences
Abstract A015: 53BP1 loss mediated PARP inhibitor resistance in BRCA1-deficient pancreatic cancer is overcome with immune checkpoint blockade

Jeffrey Patterson-Fortin,Yajie Sun,Sen Han,Zhe Li,Zuzanna Nowicka,Yuna Hirohashi,Susan Kilgas,Jae Kyo Yi,Alexander Spektor,Wojciech Fendler,Panagiotis Konstantinopoulos,Alan D. D'Andrea,Dipanjan Chowdhury

DOI: https://doi.org/10.1158/1538-7445.dnarepair24-a015

IF: 11.2

2024-01-10

Cancer Research

Abstract:Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer characterized by the presence of mutations in homologous recombination (HR) repair genes, including BRCA1 and BRCA2, in approximately 20% of diagnosed cases. 53BP1 (tumor protein p53 binding protein 1) nucleates the anti-end resection machinery at DNA double strand break (DSB)s thereby countering BRCA1 activity. Importantly, BRCA1-deficient PDACs that are typically sensitive to poly-ADP ribose polymerase inhibitors (PARPi) become resistant in the absence of 53BP1. Here, we demonstrate that loss of 53BP1 results in enhanced DNA end-resection, increased micronuclei, and cytoplasmic dsDNA, leading to activation of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway, activating pro-inflammatory signaling. This not only enhances CD8+ T cell infiltration but also activates macrophages and natural killer (NK) cells culminating in tumor growth inhibition. Loss of 53BP1 correlates with response to immune checkpoint blockade (ICB) and improved overall survival. Finally, BRCA1-deficient tumors that develop resistance to PARPi due to the loss of 53BP1 are susceptible to ICB. Taken together, our findings provide a rationale for combining PARPi with ICB to overcome PARPi-resistance in BRCA1-deficient pancreatic cancers. Citation Format: Jeffrey Patterson-Fortin, Yajie Sun, Sen Han, Zhe Li, Zuzanna Nowicka, Yuna Hirohashi, Susan Kilgas, Jae Kyo Yi, Alexander Spektor, Wojciech Fendler, Panagiotis Konstantinopoulos, Alan D. D'Andrea, Dipanjan Chowdhury. 53BP1 loss mediated PARP inhibitor resistance in BRCA1-deficient pancreatic cancer is overcome with immune checkpoint blockade [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: DNA Damage Repair: From Basic Science to Future Clinical Application; 2024 Jan 9-11; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2024;84(1 Suppl) nr A015.

oncology
Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition

Lu Yang,Youyou Zhang,Weiwei Shan,Zhongyi Hu,Jiao Yuan,Jingjiang Pi,Yueying Wang,Lingling Fan,Zhaoqing Tang,Chunsheng Li,Xiaowen Hu,Janos L Tanyi,Yi Fan,Qihong Huang,Kathleen Montone,Chi V Dang,Lin Zhang,Janos L. Tanyi,Chi V. Dang

DOI: https://doi.org/10.1126/scitranslmed.aal1645

IF: 17.1

2017-07-26

Science Translational Medicine

Abstract:PARP inhibitors can be combined with BET inhibitors to treat cancers with de novo or acquired resistance to PARP inhibition.

cell biology,medicine, research & experimental
FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism

Huixian Miao,Huangyang Meng,Yashuang Zhang,Tian Chen,Lin Zhang,Wenjun Cheng

DOI: https://doi.org/10.1038/s41418-024-01263-z

IF: 12.067

2024-02-20

Cell Death and Differentiation

Abstract:Poly ADP-ribose polymerase inhibitors (PARPis) exhibit promising efficacy in patients with BRCA mutations or homologous repair deficiency (HRD) in ovarian cancer (OC). However, less than 40% of patients have HRD, it is vital to expand the indications for PARPis in BRCA-proficient patients. Ferroptosis suppressor protein 1 (FSP1) is a key protein in a newly identified ferroptosis-protective mechanism that occurs in parallel with the GPX4-mediated pathway and is associated with chemoresistance in several cancers. Herein, FSP1 is reported to be negatively correlated with the prognosis in OC patients. Combination therapy comprising olaparib and iFSP1 (a FSP1 inhibitor) strongly inhibited tumour proliferation in BRCA-proficient OC cell lines, patient-derived organoids (PDOs) and xenograft mouse models. Surprisingly, the synergistic killing effect could not be reversed by ferroptosis inhibitors, indicating that mechanisms other than ferroptosis were responsible for the synergistic lethality. In addition, cotreatment was shown to induce increased γH2A.X foci and to impair nonhomologous end joining (NHEJ) activity to a greater extent than did any single drug. Mass spectrometry and immunoprecipitation analyses revealed that FSP1 interacted with Ku70, a classical component recruited to and occupying the end of double-strand breaks (DSBs) in the NHEJ process. FSP1 inhibition decreased Ku70 PARylation, impaired subsequent DNA-PKcs recruitment to the Ku complex at DSB sites and was rescued by restoring PARylation. These findings unprecedentedly reveal a novel role of FSP1 in DNA damage repair and provide new insights into how to sensitize OC patients to PARPi treatment.

cell biology,biochemistry & molecular biology
CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancer

Yite Xue,Taotao Yin,Shuo Yuan,Lingfang Wang,Hui Lin,Tianzhe Jin,Ruiyi Xu,Jiaxin Gu,Shizhen Shen,Xiaojing Chen,Zhuoye Chen,Ni Sima,Lifeng Chen,Weiguo Lu,Xiao Li,Xiaodong Cheng,Hui Wang

DOI: https://doi.org/10.1016/j.drup.2024.101151

IF: 22.841

2024-10-13

Drug Resistance Updates

Abstract:Introduction Ovarian cancer is the most lethal gynecological cancer and presents significant therapeutic challenges. The discovery of synthetic lethality between PARP inhibitors (PARPi) and homologous recombination deficiency marked a new era in treating BRCA1/2-mutated tumors. However, PARPi resistance remains a major clinical challenge. Methods RNA sequencing was used to identify genes altered by PARPi treatment and LC-MS was used to detect proteins interacting with CYP1B1. Resistance mechanisms were explored through ATAC-seq and gene expression manipulation. Additional techniques, including micrococcal nuclease digestion assays, DAPI staining, and fluorescence microscopy, were used to assess changes in nuclear morphology and chromatin accessibility. Results The gradual exposure of Olaparib has developed a PARPi-resistant cell line, A2780-OlaR, which exhibits significant upregulation of CYP1B1 at both RNA and protein levels. Down-regulating CYP1B1 expression or using specific inhibitors decreased the cellular response to Olaparib. Linker histone H1.4 was identified as associated with CYP1B1. ATAC-seq showed differential chromatin accessibility between A2780-OlaR and parental cells, indicating that the downregulation of H1.4 was associated with increased chromatin accessibility and higher cell viability after Olaparib treatment. Conclusion Our findings reveal a novel role for CYP1B1 in driving PARPi resistance through distinct molecular mechanisms in A2780-OlaR. This study highlights the importance of chromatin accessibility in PARPi efficacy and suggests the CYP1B1/H1.4 axis as a promising therapeutic target for overcoming drug resistance in ovarian cancer, offering potentially therapeutic benefits.

pharmacology & pharmacy
Differential Immunomodulatory Effect of PARP Inhibition in BRCA1 Deficient and Competent Tumor Cells

Isabel Alvarado-Cruz,Mariam Mahmoud,Mohammed Khan,Shilin Zhao,Sebastian Oeck,Rithy Meas,Kaylyn Clairmont,Victoria Quintana,Ying Zhu,Angelo Porciuncula,Hailey Wyatt,Shuangge Ma,Yu Shyr,Yong Kong,Patricia M. LoRusso,Daniel Laverty,Zachary D. Nagel,Kurt A. Schalper,Michael Krauthammer,Joann B. Sweasy

DOI: https://doi.org/10.1016/j.bcp.2020.114359

IF: 6.1

2021-01-01

Biochemical Pharmacology

Abstract:Poly-ADP-ribose polymerase (PARP) inhibitors are active against cells and tumors with defects in homology-directed repair as a result of synthetic lethality. PARP inhibitors (PARPi) have been suggested to act by either catalytic inhibition or by PARP localization in chromatin. In this study, we treat BRCA1 mutant cells derived from a patient with triple negative breast cancer and control cells for three weeks with veliparib, a PARPi, to determine if treatment with this drug induces increased levels of mutations and/or an inflammatory response. We show that long-term treatment with PARPi induces an inflammatory response in HCC1937 BRCA1 mutant cells. The levels of chromatin-bound PARP1 in the BRCA1 mutant cells correlate with significant upregulation of inflammatory genes and activation of the cyclic GMP-AMP synthase (cGAS)/signaling effector stimulator of interferon genes (STING pathway). In contrast, an increased mutational load is induced in BRCA1-complemented cells treated with a PARPi. Our results suggest that long-term PARP inhibitor treatment may prime both BRCA1 mutant and wild-type tumors for positive responses to immune checkpoint blockade, but by different underlying mechanisms.
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors

Zhaozhen Wu,Pengfei Cui,Haitao Tao,Sujie Zhang,Junxun Ma,Zhefeng Liu,Jinliang Wang,Yuanyu Qian,Shixue Chen,Ziwei Huang,Xuan Zheng,Di Huang,Yi Hu

DOI: https://doi.org/10.1177/1179554921996288

2021-01-01

Abstract:Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated great promise for treating cancers with homologous recombination (HR) defects, such as germline BRCA1/2 mutation. Further studies suggest that PARP inhibitors (PARPi) can also exhibit efficacy in HR-competent cancers, by amplifying the DNA damage and inducing immunogenic cell death, and PARPi lead to increasing tumor neoantigen, upregulation of interferons and PD-L1, and modulation of the tumor microenvironment, which may facilitate a more profound antitumor immune response. Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 or CTLA-4 have achieved impressive success in the treatment of different malignancies. However, only a subset of populations derive clinical benefit, and the biomarkers and resistance mechanisms are not fully understood. Therefore, given that PARPi could potentiate the therapeutic effect of ICIs, PARPi combined with ICIs are becoming an alternative for patients who cannot benefit from ICI monotherapy. In this review, we focus on the mechanisms and immune role of PARPi and discuss the rationale and clinical studies of this combined regimen.
Fan1 Acts with Fanci-Fancd2 to Promote Dna Interstrand Cross-Link Repair

Ting Liu,Gargi Ghosal,Jingsong Yuan,Junjie Chen,Jun Huang

DOI: https://doi.org/10.1126/science.1192656

IF: 56.9

2010-01-01

Science

Abstract:Fanconi anemia (FA) is caused by mutations in 13 Fanc genes and renders cells hypersensitive to DNA interstrand cross-linking (ICL) agents. A central event in the FA pathway is mono-ubiquitylation of the FANCI-FANCD2 (ID) protein complex. Here, we characterize a previously unrecognized nuclease, Fanconi anemia-associated nuclease 1 (FAN1), that promotes ICL repair in a manner strictly dependent on its ability to accumulate at or near sites of DNA damage and that relies on mono-ubiquitylation of the ID complex. Thus, the mono-ubiquitylated ID complex recruits the downstream repair protein FAN1 and facilitates the repair of DNA interstrand cross-links.

Figure S5 from FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer

Figure S2 from FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer

Figure S7 from FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer

Abstract 7220: Emerging combination strategy: FANCI suppression induces PARP1 redistribution to enhance efficacy of PARP inhibitors in breast cancer

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways

Targeting FEN1 to enhance efficacy of PARP inhibition in triple-negative breast cancer

BRMS1 Participates in Regulating Cell Sensitivity to DNA Interstrand Crosslink Damage by Interacting with FANCI

A two-step mechanism governing PARP1-DNA retention by PARP inhibitors

Abstract A015: 53BP1 loss mediated PARP inhibitor resistance in BRCA1-deficient pancreatic cancer is overcome with immune checkpoint blockade

Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition

FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism

CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancer

Differential Immunomodulatory Effect of PARP Inhibition in BRCA1 Deficient and Competent Tumor Cells

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors

Fan1 Acts with Fanci-Fancd2 to Promote Dna Interstrand Cross-Link Repair